In a 2-pronged move, the FDA approved the sale of the Dexcom G6 integrated continuous glucose monitoring system for determining blood glucose levels and also classified the unit as a class II medical device, enabling a speedier review for similar future systems.
In a 2-pronged move, the FDA approved the sale of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose levels and also classified the unit as a less-stringent class II medical device, enabling a speedier review for similar future systems.
The FDA said other developers of future iCGM systems could “bring their products to market in the least burdensome manner possible.” It is the FDA’s first approval for this type of device.
The Dexcom G6 is cleared for use in children 2 years and older and adults with diabetes. Nearly 10% of Americans have diabetes.
The Dexcom G6 is part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management, including mobile health apps.
“The ability of this device to work with different types of compatible devices gives patients the flexibility to tailor their diabetes management tools to best meet personal preferences,” Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, said in a statement. “In addition, the FDA has taken steps to expedite the review process for similar, integrated CGMs and make these types of systems available to patients as quickly as possible while also helping to ensure their safety and reliability.”
Continuous glucose monitoring systems that were first marketed had a different intended use and were evaluated through the FDA’s premarket approval pathway, the most rigorous review designed for the “highest risk” class III medical devices.
The FDA said it recognized the Dexcom G6 is as an opportunity to reduce regulatory burdens. Future iCGMs that meet the special controls criteria can go through a more streamlined premarket review known as 510(k) clearance.
The Dexcom G6 is a patch device, about the size of a quarter, that is applied to the skin of the abdomen and contains a small sensor that continuously measures the amount of glucose in body fluid. The device transmits real-time glucose readings every 5 minutes to a compatible display device, such as a mobile medical app on a cell phone, and it will trigger an alarm when a patient’s blood sugar enters a danger zone, soaring too high or dropping too low.
If it’s integrated with an automated insulin dosing system, a rise in blood sugar would trigger the release of insulin from the pump. The patch device should be replaced every 10 days.
An earlier version, the Dexcom G5, won FDA approval in 2016 but was not designed as an integrated system to be used with compatible devices. Unlike the earlier model, the Dexcom G6 version is factory calibrated and does not require users to calibrate the sensor with fingerstick blood glucose measurements. In addition, it has an updated sensor probe that minimizes interference with the pain reliever acetaminophen.
The FDA evaluated data from 2 clinical studies of the Dexcom G6, which included 324 adults and children aged 2 years and older. Both studies included multiple clinical visits within a 10-day period. System readings were compared to a laboratory test method that measures blood glucose values. No serious adverse events were reported.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen